Newswise — TAMPA, Fla. — Cancer treatment can be physically, mentally and emotionally taxing. Patients report disruptions in sleep and physical activity, as well as fatigue and depression. Strategies to manage or inhibit these treatment related symptoms are few. And research hoping to uncover a biological cause for the symptoms has been limited.
Moffitt Cancer Center researchers having been investigating what may trigger treatment related symptoms in patients with gynecologic cancers. In a new study published in the journal Cancers, they evaluated the relationship between inflammatory biomarkers and self-reported treatment related symptoms among this patient population.
“What makes our study unique is that it was a controlled comparison. Previous studies have evaluated treatment related symptoms in patients with different cancer types, but ours compared patient reported data with cancer free participant data,” said Aasha Hoogland, Ph.D., lead study author and applied research scientist in the Health Outcomes and Behavior Department at Moffitt.
The study included 121 gynecologic cancer patients, as well as 105 cancer free participants. Patients completed assessments and provided blood samples before chemotherapy cycles one, three and six, as well as six and 12 months after treatment. Cancer free participants were assessed at similar timepoints. The goal was to examine the longitudinal relationships among changes in pro- and anti-inflammatory markers, such as c-reactive protein, TNF-alpha, IL-10, IL-1b, IL-6, IL-1ra, TNFR1 and TNFR2, and treatment related symptoms (fatigue, depression, sleep and physical activity) in women with gynecologic cancers during and after chemotherapy.
“Specifically, we wanted to know if higher levels of inflammation were associated with worse treatment related symptoms,” Hoogland said.
Their results showed that fatigue, depression and sleep disturbance were higher among the patient population than the cancer free group. Physical activity was lower in patients before treatment and improved over time. The researchers determined most of the inflammatory markers were not associated with treatment related symptoms. However, higher c-reactive protein was associated with greater depression and less physical activity among both patients and the cancer free group.
“While this finding was interesting, it suggests there may be other causal mechanisms of treatment related symptoms among gynecologic cancer patients beyond inflammation,” said Heather Jim, Ph.D., study author and co-leader of Moffitt’s Health Outcomes and Behavior Program.
Additional research is needed to identify other biological mechanisms of symptoms and examine whether reductions in inflammation can reduce the severity of symptoms in patients treated with chemotherapy. Such interventions may considerably improve the quality of life in patients with gynecologic cancer treated with chemotherapy.
This study was supported by the National Cancer Institute (R01CA164109; U54CA163071, U54CA163068 P30CA076292).
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 54 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 8,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
###
RSS